Mark W. Geraci

15.1k citations

122 papers · 7.4k indexed · 3 hit papers · h-index 43

Impact in

Pulmonary and Respiratory Medicine top 0.5%
- Pulmonary Hypertension Research and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neonatal Respiratory Health Research
Cancer Research top 1%
- Cancer-related molecular mechanisms research

Papers in

Cancer Research 35
- MicroRNA in disease regulation 12
- Cancer-related molecular mechanisms research 11
- Cancer, Lipids, and Metabolism 11
Pulmonary and Respiratory Medicine 59
- Pulmonary Hypertension Research and Treatments 41
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 14
- Neonatal Respiratory Health Research 11

Co-authors: Rubin M. Tuder Norbert F. Voelkel Carlyne D. Cool Mark D. Moore Heiko Golpon Christopher D. Coldren James E. Loyd Raphael A. Nemenoff
Journals: CHEST Journal (14 papers)American Journal of Respiratory and Critical Care Medicine (9 papers)American Journal of Respiratory Cell and Molecular Biology (7 papers)American Journal of Physiology-Lung Cellular and Molecular Physiology (5 papers)Cancer Prevention Research (5 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Mark W. Geraci

119 papers receiving 7.3k citations

Hit Papers

align trajectories log scale

Genetics and Genomics of Pulmonary Arterial Hypertension 2013 · 359 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Journal of the American College of Cardiology
2012 Nature Medicine
2001 The Journal of Pathology

Peers

Countries citing papers authored by Mark W. Geraci

Since Specialization

Citations

This map shows the geographic impact of Mark W. Geraci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Geraci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Geraci more than expected).

Fields of papers citing papers by Mark W. Geraci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Geraci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Geraci. The network helps show where Mark W. Geraci may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark W. Geraci, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark W. Geraci Line = papers co-authored together Mark W. Geraci links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of P2Y12 Inhibitors, SGLT2 Inhibitors and P-Selectin Inhibitors on One-year Quality-of-Life Outcomes in Critically Ill Patients Hospitalized for COVID-19: A Pre-specified Secondary Analysis of the ACTIV4a Randomized Clinical Trial American Journal of Respiratory and Critical Care Medicine ·Moha Asri Abdullah, Lior Liba, Jeffrey S. Berger, Mark W. Geraci, Michelle N. Gong, Lucy Z. Kornblith, Mikhail Kosiborod, Patrick R. Lawler, Frank C. Sciurba, Scott D. Solomon, Lana Wahid, Judith S. Hochman, Matthew D. Neal, Stephen R. Wisniewski, Christine M. Leeper	2025	1
2	Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development International Journal of Molecular Sciences ·Elizabeth A. Mickler, Huaxin Zhou, Tzu Phang, Mark W. Geraci, Robert S. Stearman, Catherine R. Sears	2021	0
3	A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers Cancer Prevention Research ·Robert L. Keith, Patrick J. Blatchford, Daniel T. Merrick, Paul A. Bunn, Anis Suhaina Ishak, Lori D. Dwyer‐Nield, Alexei Komkov, Mark W. Geraci, York E. Miller	2019	19
4	Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension American Journal of Respiratory Cell and Molecular Biology ·Hannes Hudalla, Zoe Michael, Nicolas Christodoulou, Gareth R. Willis, Angeles Fernandez‐Gonzalez, Songqi Li, Paul B. Dieffenbach, Laura E. Fredenburgh, Robert S. Stearman, Mark W. Geraci, Stella Kourembanas, Helen Christou	2019	60
5	TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Europe PMC (PubMed Central) ·Mark W. Geraci	2018	3
6	Training the physician-scientist: views from program directors and aspiring young investigators JCI Insight ·Christopher S. Williams, Audra N. Iness, Rebecca M. Baron, Olujimi A. Ajijola, Patrick J Hu, Jatin M. Vyas, Robert A. Baiocchi, Alexander J. Adami, Jeremie M. Lever, Peter S. Klein, Linda L. Demer, Michael P. Madaio, Mark W. Geraci, Lawrence F. Brass, Melvin Blanchard, Robert A. Salata, Mone Zaidi	2018	24
7	The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model Cancer Prevention Research ·Lori D. Dwyer‐Nield, Gregory A. Hickey, Alessandra Sereno, Kevin S. Choo, Debbie G. McArthur, Meredith A. Tennis, Maria Maddalena Grattagliano, Mark W. Geraci, Robert L. Keith	2017	8
8	Speckle Tracking Echocardiography to Evaluate for Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease COPD Journal of Chronic Obstructive Pulmonary Disease ·Jessica L. Rice, Sally Westwood, 理子高田, Mark W. Geraci, R. William Vandivier, Jennifer L. Dorosz, Todd Bull	2016	9
9	Transcriptional Impact of Rare and Private Copy Number Variants in Hypoplastic Left Heart Syndrome Clinical and Translational Science ·G. N’goala, Shelley D. Miyamoto, Paul Grossfeld, David E. Clouthier, Christopher D. Coldren, Robert S. Stearman, Mark W. Geraci	2015	13
10	Application of SNP Microarrays to the Genome-Wide Analysis of Chromosomal Instability in Premalignant Airway Lesions Cancer Prevention Research ·Ichiro Nakachi, Jessica L. Rice, Christopher D. Coldren, Michael G. Edwards, Robert S. Stearman, G. N’goala, Marileila Varella‐Garcia, Wilbur A. Franklin, Robert L. Keith, 谢凡, Bifeng Gao, Daniel T. Merrick, York E. Miller, Mark W. Geraci	2013	18
11	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers Cancer Prevention Research ·Robert L. Keith, Patrick J. Blatchford, John Kittelson, John D. Minna, Karen Kelly, Pierre P. Massion, Wilbur A. Franklin, Jenny Mao, David O. Wilson, Daniel T. Merrick, Fred R. Hirsch, Timothy C. Kennedy, Paul A. Bunn, Mark W. Geraci, York E. Miller	2011	72
12	Prostacyclin Inhibits IFN-γ-Stimulated Cytokine Expression by Reduced Recruitment of CBP/p300 to STAT1 in a SOCS-1-Independent Manner The Journal of Immunology ·Derek Strassheim, 由夫三村, Danielle Burke, Mark W. Geraci, Kurt R. Stenmark	2009	23
13	A Macrophage Gene Expression Signature Defines a Field Effect in the Lung Tumor Microenvironment Cancer Research ·Robert S. Stearman, Lori D. Dwyer‐Nield, Michael C. Grady, Alvin M. Malkinson, Mark W. Geraci	2008	38
14	Prostaglandin I2 Analogs Inhibit Proinflammatory Cytokine Production and T Cell Stimulatory Function of Dendritic Cells The Journal of Immunology ·Weisong Zhou, Koichi Hashimoto, Kasia Goleniewska, Jamye F. O’Neal, Shaoquan Ji, Timothy S. Blackwell, Garret A. FitzGerald, Karine Egan, Mark W. Geraci, R. Stokes Peebles	2007	133
15	Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines Molecular Cancer Research ·Christopher D. Coldren, Barbara A. Helfrich, Samir E. Witta, Michio Sugita, Razvan Lapadat, Chan Zeng, Mi Hye Yi, Wilbur A. Franklin, Fred R. Hirsch, Mark W. Geraci, Paul A. Bunn	2006	107
16	Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension American Journal of Respiratory and Critical Care Medicine ·Todd Bull, Christopher D. Coldren, Mark D. Moore, Sylk Sotto‐Santiago, Ambika C.A., S. Patrick Nana‐Sinkam, Norbert F. Voelkel, Mark W. Geraci	2004	120
17	Pigment Epithelium–derived Factor in Idiopathic Pulmonary Fibrosis American Journal of Respiratory and Critical Care Medicine ·Gregory P. Cosgrove, Kevin K. Brown, William P. Schiemann, Amanda E. Serls, Jane E. Parr, Mark W. Geraci, Marvin I. Schwarz, Carlyne D. Cool, G. Scott Worthen	2004	205
18	Janus face of vascular endothelial growth factor: The obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension Critical Care Medicine ·Norbert F. Voelkel, Carlyne D. Cool, C. Steggell, Mark W. Geraci, Michael E. Yeager, Todd M. Bull, Michael Kasper, Rubin M. Tuder	2002	75
19	Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension Journal of Clinical Investigation ·Mark W. Geraci, Bifeng Gao, David Shepherd, Mark D. Moore, Jay Y. Westcott, Karen A. Fagan, PANAYIU YANNACOPULU, Rubin M. Tuder, Norbert F. Voelkel	1999	166
20	Novel Bombesin-Like Peptide Binding Proteins from Lung American Journal of Respiratory Cell and Molecular Biology ·Mark W. Geraci, Y E Miller, Jovan Ljubenkovic, Madeleine Kane	1994	6

About Mark W. Geraci

Mark W. Geraci is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Biochemistry, Oncology and Pharmacology, having authored 122 papers that have together received 7.4k indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (41 papers), Inflammatory mediators and NSAID effects (14 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers), RNA modifications and cancer (12 papers), MicroRNA in disease regulation (12 papers), Neonatal Respiratory Health Research (11 papers), Cancer-related molecular mechanisms research (11 papers) and Cancer, Lipids, and Metabolism (11 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.7k citations), Cancer Research (1.3k citations), Cardiology and Cardiovascular Medicine (1.2k citations), Critical Care and Intensive Care Medicine (257 citations) and Biochemistry (318 citations). Mark W. Geraci has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Rubin M. Tuder, Norbert F. Voelkel, Carlyne D. Cool, Mark D. Moore, Heiko Golpon, Christopher D. Coldren, James E. Loyd, Raphael A. Nemenoff, Robert L. Keith and Bifeng Gao. Their work appears in journals such as CHEST Journal, American Journal of Respiratory and Critical Care Medicine, American Journal of Respiratory Cell and Molecular Biology, American Journal of Physiology-Lung Cellular and Molecular Physiology and Cancer Prevention Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact